Background and rationale: 
In Australia, despite improvements in diagnosis and care, the five-year survival for people with multiple myeloma (MM) is only 43%. MM is also associated with a high burden of disease which compromises patients’ health-related quality of life (HRQOL). Although improved overall survival remains a major goal of cancer treatment, HRQOL is increasingly important to patients and clinicians. However, few data exist on optimal measures to improve QOL in patients with MM. Involving patients in their care using patient-reported outcomes warrants investigation. 

This pilot randomised study leverages the infrastructure and recruitment of the MRDR to test the feasibility of using a HRQOL questionnaire for MM as an intervention by reporting concerning results to clinicians in real time at patient visits. The MyPOS questionnaire was developed for use in the clinical setting and raises questions that can be overlooked by patients and busy clinicians. If treating clinicians were aware of issues that significantly impact patients’ HRQOL but that can be easily overlooked in busy clinical settings, patients could benefit.

If feasibility of the use of patient-reported outcomes as an intervention is demonstrated, we anticipate progression to a larger study to assess health benefits of the intervention and its impact on HRQOL. Results of this study may be readily translatable to other blood and solid cancers and patient groups.